Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM PlatformRUTHERFORD, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.(“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that the US Patent and Trademark Office (USPTO) has issued Patent Nos. US 12,453,494, US 12,458,257, and US 12,458,258 for the Company’s continuous blood glucose monitoring (CBGM) platform. The patents strengthen Glucotrack’s competitive position and intellectual property protection as the Company advances its multi-year, fully implantable CBGM system toward commercialization.
Glucotrack, Inc. Encourages Shareholders to VoteThe Special Meeting of Shareholders reconvenes on November 7, 2025
Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory TeamRenowned pain management and medical technology leader to accelerate Glucotrack’s strategy for integrated glucose monitoring applications, building on Company’s 2024 expansion into epidural monitoring
Glucotrack, Inc. Reminds Shareholders to VoteThe Special Meeting of Shareholders held on October 31, 2025
Q3 Virtual Investor Summit: On-Demand Presentations Now AvailableNEW YORK, NY / ACCESS Newswire / September 30, 2025 / Investor Summit Group is pleased to announce that presentations from the Q3 Virtual Investor Summit are now accessible for on-demand viewing. Investors and attendees who were unable to join the live event can now explore company updates and insights at their convenience.
Presenting at the Investor Summit Q3 2025 on September 16; Watch the Live Stream for FreeNEW YORK, NY / ACCESS Newswire / September 16, 2025 / Investor Summit Group, the premier destination for virtual microcap conferences, is proud to announce the schedule for its upcoming Q3 Investor Summit Virtual on Sept 16, 2025.
Glucotrack to Participate in the Q3 Virtual Investor SummitRUTHERFORD, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that management will present and participate in one-on-one meetings with investors at the Q3 Virtual Investor Summit, being held on September 16-17, 2025.
Glucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, CardiologyExperienced cardiac electrophysiologist joins Glucotrack’s growing clinical advisory team as the Company advances its long-term CBGM through critical clinical milestones
Glucotrack to Exhibit at 2025 Association of Diabetes Care and Education Specialists Annual MeetingCompany to present endocrinologist perspectives on implantable CBGM technology as it advances toward US pilot study
Glucotrack Announces Repurchase of Series A WarrantsWarrant buyback extinguishes warrant liability accounting and share dilution overhang
Rebuilding Trust: How Glucotrack Is Establishing A New Standard In Diabetes ManagementDETROIT, MICHIGAN - June 10, 2025 ( NEWMEDIAWIRE ) - While the genesis of typical modern medical technologies focuses on a specific design element or research protocol, for Glucotrack Inc. (
NASDAQ: GCTK), the basis of innovation begins at the human level. It’s the reason why earlier this year, the medical device firm – which specializes in the development of a fully implantable continuous blood glucose monitoring (CBGM) system – formed a Patient Advisory Board (PAB).
Rebuilding Trust: How Glucotrack Is Establishing A New Standard In Diabetes ManagementSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhDExperienced medical device executive with deep expertise in implantable technologies joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology
Glucotrack Establishes Patient Advisory Board to Inform Diabetes Technology DevelopmentPatients get a seat at the table in development of long-term implantable continuous blood glucose monitoring technology
First-In-Human Study In The Bag, Glucotrack Gears Up For Long-Term Trial Of Potentially Groundbreaking Continuous Blood Glucose Monitor For Diabetes PatientsDETROIT, MICHIGAN - May 14, 2025 ( NEWMEDIAWIRE ) - Among the more challenging chronic conditions, diabetes represents both a social and economic burden, particularly for insulin-dependent cases . According to the National Diabetes Statistics Report, 38.4 million people of all ages - or 11.6% of the U.S. population – had diabetes. Of this, 1.7 million adults aged 20 years or older – or 5.7% of all U.S. adults with diagnosed diabetes – reported having the type 1 variant and using insulin.
Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic PancreasContinuous Blood Glucose Monitor will be integrated with automated insulin delivery system for major EU diabetes study
Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose MonitorNext Generation AI-Driven Analytics to Unlock Key Insights from the Ongoing Continuous Blood Glucose Monitoring Clinical Study Data
Implantable, Hidden Continuous Glucose Monitoring Could Revolutionize Diabetes CareSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Implantable, Hidden Continuous Glucose Monitoring Could Revolutionize Diabetes CareDETROIT, MICHIGAN - March 19, 2025 ( NEWMEDIAWIRE ) - Paul Goode, President & CEO, GlucoTrack (
NASDAQ: GCTK), was recently a guest on Benzinga’s All-Access.
